Yvonne Nowosielski

Yvonne Nowosielski

Auto-generated profile, based on publicly available information

Yvonne Nowosielski

Department of Ophthalmology and Optometry, Medical University of Innsbruck, Innsbruck, Austria

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2024 in Eye
Verified
Journal Article
Open access
PDF file
TRTeresa Rauchegger
Teresa Rauchegger
SKSarah-Maria Krause
Sarah-Maria Krause
YNYvonne Nowosielski
Yvonne Nowosielski
AHAnna Lena Huber
Anna Lena Huber
PWPeter Willeit
Peter Willeit
BTBarbara Teuchner
Barbara Teuchner
Objective: To reliably compare the three-year clinical outcome and safety of XEN45 Gel Stent implantation (XEN) vs. trabeculectomy (TRAB) in patients with glaucoma. Subject/methods: We conducted a retrospective cohort study with patients with primary open angle or pseudoexfoliation glaucoma with uncontrolled intraocular pressure (IOP) undergoing XEN or TRAB at the Innsbruck University Clinic of Ophthalmology and Optometry, Austria and analysed changes in IOP, numbers of IOP-lowering medications, and complete surgical success (i.e., IOP ≤ 18 mmHg, ≥20% IOP reduction and not requiring IOP-lowering medication) up to 36 months postoperatively. Results: Between 2013 and 2019, we performed XEN Gel Stent implantation in 58 eyes and trabeculectomy in 84 eyes. From baseline to 36 months, mean IOP decreased from 23.4 to 13.8 mmHg (mean reduction 35%, 95% confidence interval 23–48%, p < 0.001) in the XEN group and from 25.1 to 11.2 mmHg (mean reduction 50%, 41–60%, p < 0.001) in the TRAB group. TRAB provided higher IOP reduction than XEN Gel Stent implantation at 12, 24, and 36 months (all p < 0.05). In XEN versus TRAB, IOP-lowering medication was required by 98.3% vs. 97.6% before surgery (p = 0.781), differed significantly at month 12 (43.2% vs. 2.0%, p < 0.001)but not at month 24 or 36. Complete surgical success was achieved in 40.0% vs. 62.8% at month 24 (adjusted odds ratio 2.70; 1.04–7.00, p = 0.040) and 27.3% vs. 56.8% at month 36 (4.36; 1.25–15.18, p = 0.021). Conclusion: Compared to XEN, TRAB was associated with lower intraocular pressure, less IOP-lowering medication, and higher probability of achieving complete surgical success over a 36-month follow-up period.

1 November 2021 in Retina
Verified
Journal Article
Open access
RAReinhard Angermann
Reinhard Angermann
AHAnna Lena Huber
Anna Lena Huber
YNYvonne Nowosielski
Yvonne Nowosielski
SSStefan Salcher
Stefan Salcher
TGThomas Gasser
Thomas Gasser
CZClaus Zehetner
Claus Zehetner
Purpose: To analyze and compare the effects of intravitreal brolucizumab versus aflibercept on systemic vascular endothelial growth factor (VEGF)-A levels in patients with neovascular age-related macular degeneration. Methods: In this prospective interventional case series study, brolucizumab (6.0 mg/50 µL) or aflibercept (2.0 mg/50 µL) was injected intravitreally in 30 patients each. Blood samples were drawn at baseline and 7 days and 28 days after the first injection. Systemic VEGF-A levels were measured using enzyme-linked immunosorbent assay. Thirty healthy individuals served as controls. Results: The median baseline systemic VEGF-A levels in the brolucizumab, aflibercept, and control groups were 10.8 (8.0–13.2), 12.0 (8.0–18.5), and 10.0 (8.0–15.1) pg/mL, respectively (P = 0.315). In the brolucizumab group, VEGF-A levels significantly decreased to 8.0 (8.0–11.5) pg/mL on Day 7 (P = 0.0254) and to 8.0 (8.0–8.0) pg/mL on Day 28 (P < 0.001). In the aflibercept group, VEGF-A levels significantly decreased to 8.0 (8.0–8.0) pg/mL on Day 7 (P < 0.001) but returned to the baseline level, 12.5 (8.5–14.6) pg/mL, on Day 28 (P = 0.120). Vascular endothelial growth factor–A levels were significantly different between the treatment groups after 28 days (P < 0.001). Conclusion: Intravitreal brolucizumab resulted in a sustained reduction of systemic VEGF-A levels until 28 days posttreatment, which raises concerns regarding its safety and long-term effects.

9 May 2025 in Wiener Medizinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
APAlisa Pedrini
Alisa Pedrini
YNYvonne Nowosielski
Yvonne Nowosielski
MRMatus Rehak
Matus Rehak

8 February 2025 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
AHAnna Lena Huber
Anna Lena Huber
ABAngelika Bauer
Angelika Bauer
JBJulius Beirer
Julius Beirer
KFKatharina Frede
Katharina Frede
KKKatharina Kirchmair
Katharina Kirchmair
YNYvonne Nowosielski
Yvonne Nowosielski

1 January 2021 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
AHAnna Lena Huber
Anna Lena Huber
RAReinhard Angermann
Reinhard Angermann
YNYvonne Nowosielski
Yvonne Nowosielski
CSChristof Seifarth
Christof Seifarth
MKMartina T. Kralinger
Martina T. Kralinger
CZClaus Zehetner
Claus Zehetner
Purpose . To analyze the effect of intravitreal aflibercept injections on systemic levels of insulin‐like growth factor‐1 and vascular endothelial growth factor‐A in patients with diabetic retinopathy and age‐related macular degeneration. Methods . Vascular endothelial growth factor‐A and insulin‐like growth factor‐1 levels were determined before and one week and four weeks after intravitreal injection of aflibercept (2.0 mg/50 μ l) for 19 patients with age‐related macular degeneration (mean age, 76 ± 11 years) and 18 patients with diabetic retinopathy (mean age, 64 ± 14 years). Twenty‐two healthy individuals were enrolled as controls. Results . A significant decline in systemic vascular endothelial growth factor‐A level, from 43 (30–57) pg/ml at baseline to 8 (8–8) pg/ml ( p < 0.001) at week one and 17 (8–25) pg/ml ( p = 0.0054) at week four, was observed in the age‐related macular degeneration group. In the diabetic retinopathy group, vascular endothelial growth factor‐A levels declined from 53 (35–117) pg/ml to 2 (1–5) pg/ml ( p < 0.0001) one week after injection and 16 (13–22) pg/ml four weeks after injection ( p = 0.0327). At baseline, systemic insulin‐like growth factor‐1 concentration was higher in the diabetic retinopathy group (57 [37–99] pg/ml) than in the age‐related macular degeneration group (35 [24–51] pg/ml) ( p = 0.0056). A subgroup analysis showed that patients in the proliferative diabetic retinopathy subgroup had significantly higher systemic insulin‐like growth factor‐1 concentrations (71 [44.7–243] pg/ml) than those in the nonproliferative diabetic retinopathy subgroup (43 [29–66] pg/ml) ( p = 0.0048). Conclusions . The difference between the baseline systemic insulin‐like growth factor‐1 levels of the age‐related macular degeneration and diabetic retinopathy groups and the higher insulin‐like growth factor‐1 levels in the proliferative diabetic retinopathy subgroup one week after aflibercept therapy suggest that insulin‐like growth factor‐1 may play a role in the pathomechanism of diabetic retinopathy.

18 January 2026 in International Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
RLRoman Lischke
Roman Lischke
SKSarah-Maria Krause
Sarah-Maria Krause
TRTeresa Rauchegger
Teresa Rauchegger
GHGertrud Haas
Gertrud Haas
MKMichal Koubek
Michal Koubek
MRMatus Rehak
Matus Rehak
AIM: To report and analyze cases of sterile intraocular inflammation (IOI) following intravitreal faricimab injections in patients treated for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). METHODS: This double-center case series included nine eyes of six patients who developed uveitis after faricimab therapy. Comprehensive clinical evaluation was performed, including slit-lamp examination, intraocular pressure (IOP) measurement, fluorescein and indocyanine green angiography (ICGA), and laboratory tests. Inflammatory responses were treated with topical or systemic corticosteroids, and patients were monitored for visual acuity and inflammatory activity. RESULTS: The incidence of IOI was 0.8% per patient (Innsbruck) and 0.23% (Czechia), with inflammation typically occurring between the third and sixth injection (mean interval: 10d post-injection). Inflammatory presentations ranged from anterior uveitis to posterior segment involvement. One notable case demonstrated novel choroidal hypofluorescent lesions on angiography, suggesting deeper ocular involvement. The mean patient age was 76y; five of six affected patients were female. All cases responded to local and systemic corticosteroids, with full recovery of initial visual acuity. CONCLUSION: Sterile IOI after faricimab appears to be a rare but relevant adverse event. Although the incidence falls within expected ranges for anti-vascular endothelial growth factor (anti-VEGF) agents, the observed choroidal involvement represents a potentially new safety signal. Prompt diagnosis and corticosteroid therapy are effective in all cases. Our findings support the need for vigilant post-marketing surveillance and further studies to better understand the underlying mechanisms and risk factors of faricimab-associated inflammation.